Warts-Pipeline Review, H2 2015

Warts-Pipeline Review, H2 2015

  • Products Id :- GMDHC6874IDB
  • |
  • Pages: 91
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Warts-Pipeline Review, H2 2015


Global Markets Direct's, 'Warts-Pipeline Review, H2 2015', provides an overview of the Warts's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Warts

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Warts and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Warts pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Warts

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Warts Overview 9

Therapeutics Development 10

Pipeline Products for Warts-Overview 10

Pipeline Products for Warts-Comparative Analysis 11

Warts-Therapeutics under Development by Companies 12

Warts-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Warts-Products under Development by Companies 17

Warts-Companies Involved in Therapeutics Development 19

3M Drug Delivery Systems 19

Agilvax, Inc. 20

Biogenomics Limited 21

BioMAS Ltd. 22

Biota Pharmaceuticals, Inc. 23

EpiPharm AG 24

Foamix Pharmaceuticals Ltd. 25

G&E Herbal Biotechnology Co., Ltd. 26

Helix BioPharma Corp. 27

LEO Pharma A/S 28

MediGene AG 29

NanoViricides, Inc. 30

Nielsen Biosciences, Inc. 31

Novan, Inc. 32

Novartis AG 33

Promius Pharma, LLC 34

RXi Pharmaceuticals Corporation 35

Tamir Biotechnology, Inc. 36

Zydus Cadila Healthcare Limited 37

Warts-Therapeutics Assessment 38

Assessment by Monotherapy Products 38

Assessment by Combination Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

(digoxin + furosemide)-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

854-A-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

A-101-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AP-611074-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

AS-101-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

AX-03-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Candida Albicans Antigen-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

DFD-05-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

diphencyprone-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

EPI-N06-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

HerpeCide-I-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

human papilloma virus [strains 6,11] (bivalent) vaccine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

imiquimod-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

ingenol mebutate-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

interferon alfa-2b (recombinant)-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

interferon alpha-2b (recombinant)-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

LFX-453-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

NVN-1000-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

PP-210-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

ranpirnase-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

SB-206-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

sinecatechins-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

SRT-100-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Vaccine for Cervical Cancer and Genital Warts-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Warts-Recent Pipeline Updates 77

Warts-Dormant Projects 83

Warts-Discontinued Products 84

Warts-Product Development Milestones 85

Featured News & Press Releases 85

Feb 20, 2015: Medigene receives positive decision on marketing authorisation for Veregen in 8 additional European countries 85

Sep 30, 2014: Veregen Marketing Authorization Process initiated for eight additional European countries 85

Jul 16, 2014: Paladin Labs Announces the Canadian Launch of Veregen 86

Jun 12, 2014: Medigene announces market launch of Veregen in Belgium, Denmark and Finland 86

Apr 08, 2014: Medigene and Kora Healthcare sign agreement for the commercialisation of Veregen in United Kingdom and Ireland 86

Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden 87

Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden 87

Dec 11, 2013: Medigene announces Veregen to be launched in the Czech Republic, Poland, Hungary, and Slovakia 88

Oct 01, 2013: Medigene announces market launch of Veregen in Taiwan 88

Sep 10, 2013: Medigene's Drug Veregen receives market approval in Canada 89

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

Number of Products under Development for Warts, H2 2015 10

Number of Products under Development for Warts-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Comparative Analysis by Late Stage Development, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Development, H2 2015 16

Products under Development by Companies, H2 2015 17

Products under Development by Companies, H2 2015 (Contd..1) 18

Warts-Pipeline by 3M Drug Delivery Systems, H2 2015 19

Warts-Pipeline by Agilvax, Inc., H2 2015 20

Warts-Pipeline by Biogenomics Limited, H2 2015 21

Warts-Pipeline by BioMAS Ltd., H2 2015 22

Warts-Pipeline by Biota Pharmaceuticals, Inc., H2 2015 23

Warts-Pipeline by EpiPharm AG, H2 2015 24

Warts-Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 25

Warts-Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015 26

Warts-Pipeline by Helix BioPharma Corp., H2 2015 27

Warts-Pipeline by LEO Pharma A/S, H2 2015 28

Warts-Pipeline by MediGene AG, H2 2015 29

Warts-Pipeline by NanoViricides, Inc., H2 2015 30

Warts-Pipeline by Nielsen Biosciences, Inc., H2 2015 31

Warts-Pipeline by Novan, Inc., H2 2015 32

Warts-Pipeline by Novartis AG, H2 2015 33

Warts-Pipeline by Promius Pharma, LLC, H2 2015 34

Warts-Pipeline by RXi Pharmaceuticals Corporation, H2 2015 35

Warts-Pipeline by Tamir Biotechnology, Inc., H2 2015 36

Warts-Pipeline by Zydus Cadila Healthcare Limited, H2 2015 37

Assessment by Monotherapy Products, H2 2015 38

Assessment by Combination Products, H2 2015 39

Number of Products by Stage and Target, H2 2015 41

Number of Products by Stage and Mechanism of Action, H2 2015 43

Number of Products by Stage and Route of Administration, H2 2015 45

Number of Products by Stage and Molecule Type, H2 2015 47

Warts Therapeutics-Recent Pipeline Updates, H2 2015 77

Warts-Dormant Projects, H2 2015 83

Warts-Discontinued Products, H2 2015 84

List of Figures

Number of Products under Development for Warts, H2 2015 10

Number of Products under Development for Warts-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Products, H2 2015 16

Assessment by Monotherapy Products, H2 2015 38

Number of Products by Top 10 Targets, H2 2015 40

Number of Products by Stage and Top 10 Targets, H2 2015 40

Number of Products by Top 10 Mechanism of Actions, H2 2015 42

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 42

Number of Products by Top 10 Routes of Administration, H2 2015 44

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 44

Number of Products by Top 10 Molecule Types, H2 2015 46

Number of Products by Stage and Top 10 Molecule Types, H2 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

3M Drug Delivery Systems

Agilvax, Inc.

Biogenomics Limited

BioMAS Ltd.

Biota Pharmaceuticals, Inc.

EpiPharm AG

Foamix Pharmaceuticals Ltd.

G&E Herbal Biotechnology Co., Ltd.

Helix BioPharma Corp.

LEO Pharma A/S

MediGene AG

NanoViricides, Inc.

Nielsen Biosciences, Inc.

Novan, Inc.

Novartis AG

Promius Pharma, LLC

RXi Pharmaceuticals Corporation

Tamir Biotechnology, Inc.

Zydus Cadila Healthcare Limited

Warts Therapeutic Products under Development, Key Players in Warts Therapeutics, Warts Pipeline Overview, Warts Pipeline, Warts Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com